Covid-19 roundup: Mer­ck sub­mits mol­nupi­ravir for EUA; In­dia re­sumes vac­cine ex­ports af­ter Delta surge

Mer­ck’s oral an­tivi­ral drug for Covid-19 has been sub­mit­ted to the FDA for emer­gency use au­tho­riza­tion, the com­pa­ny an­nounced Mon­day morn­ing.

The com­pa­ny, which col­lab­o­rat­ed with Ridge­back Bio­ther­a­peu­tics, an­nounced last week that mol­nupi­ravir re­duced death and hos­pi­tal­iza­tions by 50%. The sub­mis­sion for EUA is based on pos­i­tive re­sults from the Phase III tri­al. Of 385 pa­tients in the tri­al, just 28 were hos­pi­tal­ized af­ter re­ceiv­ing mol­nupi­ravir, com­pared to 53 out of 337 pa­tients on the place­bo. No pa­tients who re­ceived mol­nupi­ravir died, com­pared with eight who were on the place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER